In a finding that could reshape how medicinal chemists produce antioxidant compounds, a team of Italian researchers has developed a rapid, solvent-minimized ball-milling method for synthesizing thiazolyl–hydrazone derivatives — molecules that in laboratory tests proved to be more potent radical scavengers than vitamin C. The work, published in Results in Chemistry, combines green chemistry principles with computational modeling to deliver a class of compounds with significant promise for combating oxidative stress, the destructive process implicated in aging, cancer, and chronic disease.

The research, led by Roberto Scipione, Sebastiano Masuri, Ester Sedda, Tiziana Pivetta, Andrea Porcheddu, Maria Grazia Cabiddu, and Andrea Citarella at the University of Cagliari, tackles a long-standing challenge in synthetic chemistry: how to produce polyphenolic thiazolyl–hydrazones efficiently without drowning the process in solvents and energy. Traditional approaches require hours of refluxing in hot ethanol, consuming large volumes of solvent and generating substantial waste. The new protocol accomplishes the same transformation in two hours at room temperature using less than half a milliliter of ethanol.

The molecules at the heart of the study belong to a family of organic compounds that chemists prize for their antioxidant potential. Thiazole-containing heterocycles — five-membered rings containing both sulfur and nitrogen — are known to facilitate the decomposition of hydroperoxides and to chelate metal ions that would otherwise catalyze damaging reactions. Hydrazone linkers add a further dimension of reactivity: their nitrogen-hydrogen bonds can donate hydrogen atoms to neutralize free radicals, and the resulting radical species are stabilized through electron delocalization. When researchers attach catechol or guaiacol phenolic groups — structural motifs found in celebrated antioxidants like the polyphenols of olive oil and green tea — the molecules become even more effective at scavenging radicals, because the phenoxy radicals formed after hydrogen donation are exceptionally stable.

Oxidative stress arises when reactive oxygen and nitrogen species overwhelm the body’s endogenous antioxidant defenses. The resulting damage to lipids, proteins, and DNA is a hallmark of chronic inflammation, cancer progression, and aging. Designing small molecules that can intercept these reactive species has therefore been a major goal of medicinal chemistry for decades. The thiazolyl–hydrazone framework synthesized by the Cagliari team combines several radical-scavenging architectural elements in a single molecule, creating compounds whose potency in standardized assays exceeded that of ascorbic acid, the benchmark reference compound.

The synthetic breakthrough lies in mechanochemistry — the use of mechanical force, delivered by grinding balls in a laboratory mill, to drive chemical reactions without bulk solvent. The researchers used a Retsch MM500 mixer mill operating at 30 Hz with zirconia jars and balls, running the entire two-step sequence in a single jar without ever isolating an intermediate. In the first step, an aldehyde condenses with thiosemicarbazide to form a thiosemicarbazone; in the second, that intermediate cyclizes with a phenacyl bromide to close the thiazole ring. A catalytic amount of acetic acid and a tiny quantity of ethanol — a technique called liquid-assisted grinding, or LAG — proved essential: without any liquid additive, conversion was a dismal 10 percent, but adding ethanol at a ratio of one microliter per milligram of solid reagents pushed yields to around 85 percent.

The full telescoped protocol — both steps performed consecutively in the same jar — delivered the target compound in 80 percent yield, matching or beating the conventional two-step route that requires 12 hours of reflux at 80 °C in 25 mL of ethanol. When the team scaled the reaction up to 20 mmol using a 50 mL jar, the protocol held up remarkably well, affording a 71 percent yield with an even smaller amount of grinding liquid, simply reduced to a quarter of the original ratio. Product isolation required nothing more than adding ethanol and filtering — no column chromatography.

Green metrics quantified just how dramatic the improvement is. For the representative compound ES3, the mechanochemical route reduced solvent consumption by 99 percent, from 40.8 mL per gram of product to 0.38. The Process Mass Intensity, a measure of total material used per unit of product, plummeted from 35.3 to 2.05 — a seventeenfold improvement. The E-factor, which captures waste generation, fell from 34.3 to 1.05, roughly a thirty-threefold reduction. Reaction Mass Efficiency nearly doubled, rising from 32.3 to 57.1 percent, while overall yield climbed from 42 percent to 80 percent. These are not incremental gains; they represent a fundamental shift in the resource profile of the synthesis.

The antioxidant activity of the fifteen compounds in the series was assessed using two well-validated assays: DPPH and ABTS, both of which measure the ability of a molecule to neutralize stable free radicals. Every compound showed activity in the micromolar range, and several outperformed ascorbic acid in both assays. The standouts were those bearing the 3,4-dihydroxy (catechol) motif: compound ES26 recorded an EC50 of 8.4 μM in the DPPH assay and an extraordinary 2.59 μM in the ABTS assay, compared with 18.6 and 12.2 μM for ascorbic acid, respectively. Compounds ES27 and ES28 performed nearly as well, while several methoxy-substituted derivatives — ES9, ES16, and ES17 — also beat the vitamin C benchmark.

Density Functional Theory calculations provided mechanistic insight into why the catechol-bearing compounds are so effective. By computing bond dissociation enthalpies, ionization potentials, proton affinities, and related thermochemical descriptors, the team mapped the three canonical antioxidant pathways: hydrogen atom transfer (HAT), single-electron transfer followed by proton transfer (SET-PT), and sequential proton loss electron transfer (SPLET). The results indicate that in the gas phase, HAT is the thermodynamically preferred route, with the hydrazone NH group serving as the primary hydrogen donor in the simpler benzaldehyde-derived compounds. In vanillin-based molecules, hydrogen abstraction from the phenolic OH becomes competitive; in the catechol derivatives, abstraction from the 4-OH position is decisively favored, owing to the additional stabilization of the phenoxy radical by an intramolecular hydrogen bond with the adjacent hydroxyl group. In solution, the SPLET pathway gains relevance, as solvation stabilizes the anionic intermediates that form upon proton loss.

The structure–activity relationships that emerged are consistent with established antioxidant chemistry. Electron-releasing groups such as methoxy substituents on the thiazole ring enhance radical-scavenging activity, whereas electron-withdrawing bromine substituents diminish it — a trend that can be mitigated when a catechol group is present elsewhere in the molecule. The computational analysis of frontier molecular orbitals confirmed extensive π-conjugation across the molecules and showed how substituents tune the HOMO–LUMO gap in ways that correlate with observed reactivity. The authors note that the slightly reduced coplanarity in the dimethoxy-substituted ES26, evidenced by a dihedral angle of 172.9 degrees versus 176.95 degrees in its monomethoxy counterpart, subtly alters the electronic landscape of the frontier orbitals.

What distinguishes this study is the marriage of two agendas that are often pursued separately: the design of biologically active antioxidant scaffolds and the radical greening of the synthesis itself. Mechanochemistry has been gaining momentum across organic synthesis as a way to slash solvent use and energy input, but demonstrations that combine solvent-minimized one-pot telescoping with preparative scale-up and rigorous green-metrics accounting remain relatively rare. The Cagliari team has shown that a complex, multicomponent heterocyclic synthesis — involving condensation, cyclization, and the construction of a sulfur-nitrogen heterocycle — can be executed cleanly in a single milling jar without heating.

The implications extend beyond the laboratory bench. Antioxidant scaffolds like the thiazolyl–hydrazones synthesized here are candidates for further biological evaluation, and the authors indicate that future work will probe mechanistic aspects and explore preliminary biological evaluations to define the translational potential of these molecules. If the exceptional radical-scavenging activity observed in vitro carries through to cellular or in vivo contexts, the compounds could serve as leads for agents targeting oxidative-stress-related pathologies. And because the synthetic route is scalable, solvent-lean, and operationally simple, the barrier to producing gram quantities of these candidates for further testing is substantially lower than it would be with conventional methodology.

The study also underscores a broader lesson for the pharmaceutical and fine-chemical industries: green metrics such as PMI and E-factor are not abstract sustainability scores but concrete indicators of process quality — lower waste, lower cost, higher yield, and simpler workflows all at once. By demonstrating a sixfold reduction in reaction time, a near-total elimination of solvent, and improved yields in the same breath, the researchers have provided a compelling case study for how mechanochemistry can move from academic curiosity to practical synthetic platform.

As the search for effective antioxidant therapeutics continues, this work offers a template: design molecules around well-understood radical-stabilizing motifs, synthesize them with minimal environmental footprint, and validate their activity with rigorous in vitro and computational analysis. The thiazolyl–hydrazones that emerged from the zirconia jars in Cagliari — particularly the catechol-bearing champions ES26, ES27, and ES28 — now stand as both chemical achievements and potential starting points for the next generation of radical-scavenging agents.

For more than four decades, pathologists have glimpsed something unsettling under the microscope in the earliest stages of certain cancers: cells with nuclei far larger than they should be, swollen and distorted, lurking in tissue that otherwise appears on the verge of catastrophe. These so-called giant-nucleus cells, or karyomegalic cells, were first spotted in the 1980s in animal experiments involving iron-induced oxidative stress, yet their biological identity and their role in the genesis of cancer remained stubbornly obscure. Now, a team of researchers in Japan has provided the most detailed portrait of these cells to date, and their findings suggest that the enormous nuclei may be far more than a curiosity—they could be the founding population of early cancer, visible before any tumor exists, and potentially useful as a predictor of patient outcomes.

The study, led by Shinya Toyokuni, professor emeritus at Nagoya University Graduate School of Medicine, together with assistant professor Yingyi Kong and colleagues, was published in Redox Biology. The work addresses a deceptively simple question: when iron overload kills most cells in a tissue through oxidative damage, who survives, and what do the survivors become? Iron is an essential micronutrient, but in excess it is a potent carcinogen. Its chemistry is both the reason we need it and the reason it can harm us. Iron catalyzes the formation of hydroxyl radicals from hydrogen peroxide through the Fenton reaction, and these radicals shred DNA, oxidize lipids, and damage proteins. When the damage is severe enough, a form of programmed cell death called ferroptosis is triggered—an iron-dependent demise characterized by lipid peroxidation cascades that rupture the cell membrane. Ferroptosis has become one of the hottest topics in cancer biology precisely because it links iron metabolism, oxidative stress, and cell fate in a single mechanism.

Toyokuni’s team reasoned that if ferroptosis sweeps through iron-damaged tissue, the cells that escape it must be exceptional in some way, and those exceptions might be the seed of malignancy. To find out, they turned to a well-established animal model in which ferric nitrilotriacetate, a carcinogenic iron compound, is injected into rats, delivering a bolus of iron to the kidneys. The compound accumulates in the proximal tubules, where it catalyzes oxidative damage and, over months, produces renal cell carcinoma. In the experiments, the researchers collected kidney tissue before the injection and again one and three weeks afterward. Crucially, they also included a second experimental group: rats carrying a single mutated copy of the BRCA1 gene, the same gene that, when mutated in humans, dramatically raises the risk of breast and ovarian cancers and is associated with renal carcinoma in certain contexts.

The methodological heart of the study lies in its marriage of two technologies. The first is spatial transcriptomics, a technique that maps gene activity across individual cells within a tissue section while preserving the tissue’s original architecture—so researchers can see not only which genes are active but where in the tissue those transcriptional programs are operating. The second is computational nuclear morphometry, which quantifies the size, shape, and density of cell nuclei in the same samples. By overlaying the two datasets, the team could link the physical appearance of each cell—above all, the size of its nucleus—to its underlying transcriptional state. This integration is important because morphological atypia has long been the currency of diagnostic pathology, but connecting that atypia to molecular signatures at single-cell resolution is a recent capability.

What emerged within a week of iron administration was striking. Giant-nucleus cells appeared in the damaged kidneys, and these cells were not simply wounded cells awaiting death. They showed elevated expression of potent oncogenes, including Myc and Met, and they had acquired resistance to ferroptosis—the very cell death pathway that was eliminating their neighbors. In other words, the extreme oxidative environment had functioned as a brutal selective pressure, and the cells best adapted to survive it had activated a program that resembles, in miniature, the hallmark machinery of cancer. The enrichment of Myc, a transcription factor that drives cell growth and proliferation, and Met, a receptor tyrosine kinase involved in invasive growth, paints a picture of cells that are not merely enduring damage but reorganizing themselves around it.

The BRCA1 connection proved equally consequential. BRCA1 is best known as a guardian of the genome, a scaffold for the homologous recombination machinery that repairs double-strand DNA breaks. In the BRCA1-mutant rats, giant-nucleus cells emerged with distinctly different biological profiles from those in wild-type animals. The interpretation the researchers offer is that BRCA1 deficiency cripples DNA repair, so more of the damaged cells that would otherwise die or be repaired instead survive in their injured, genome-compromised state—becoming precancerous giant-nucleus cells. Electron microscopy and cellular respiration measurements reinforced this idea at the subcellular level: cells from BRCA1-mutant rats showed mitochondrial remodeling, with impaired iron handling and compromised respiratory function. Mitochondria, long appreciated as power plants, are also central regulators of ferroptosis and iron metabolism, and their disarray in the mutant animals may be both a consequence of BRCA1 loss and a driver of the abnormal iron biology that feeds karyomegaly.

Using their combined gene-expression and nuclear-shape data, the researchers went further and classified the giant-nucleus cells into six distinct types. One type possessed extremely large nuclei and gene signatures of stress-induced growth arrest—cells that appear to have locked themselves into a senescent-like state, consistent with profiles reported in earlier studies. Another type, found more frequently in BRCA1-mutant kidneys, showed heightened activity of cancer-related genes alongside elongated nuclei, a combination the authors interpret as a potential precancerous state. The taxonomy matters because it reframes giant-nucleus cells from a single enigmatic category into a spectrum, some members of which may be harmless or even protective while others carry genuine malignant potential.

One of the most provocative findings concerns the cells surrounding the giants. Even morphologically normal cells near giant-nucleus cells exhibited gene expression changes that appear to promote survival, suggesting that the karyomegalic cells remodel their local microenvironment in ways that extend beyond their own borders. In BRCA1-mutant kidneys, the team also documented a substantial increase in stromal cells—non-cancerous supportive cells including immune and connective tissue elements—around the damaged regions. The local tissue environment, the tumor niche in the language of modern oncology, was being reshaped long before any tumor could be called a tumor. This raises the possibility that a single conspicuous cell, easily identified by its nucleus under a conventional microscope, could serve as a sentinel for a whole neighborhood of incipient malignancy.

The leap from rat kidneys to human medicine came through two complementary analyses. First, the researchers mined TCGA-KIRC, a large public database of kidney cancer patients, asking whether tumors carrying gene-expression patterns resembling the cancer-prone giant-nucleus cells were associated with different clinical trajectories. They were: patients whose tumors shared the gene patterns of the cancer-prone giant-nucleus cells had shorter survival times, while those with patterns resembling the healthier giant-nucleus cell types had better outcomes. Not all giant-nucleus cells, in other words, are created equal, and the transcriptional fingerprints defined in the rat model appear to carry prognostic weight in human disease. Second, in a small pilot study, the team examined breast tissue from seven individuals with inherited BRCA1 mutations and fifteen without, observing abnormal nuclear features similar to those in the animal model in the mutation carriers. While the sample size is modest, the parallel hints that karyomegaly may be a cross-tissue marker of BRCA1-linked precancerous change.

The broader implications run in two directions. Clinically, the promise is that giant-nucleus cells, being easy to spot under the microscope, could function as early indicators of cancer—visible warnings in tissue that would otherwise be classified as merely damaged or inflamed. The TCGA survival data suggest that their gene-expression signatures might even stratify patients by risk once a tumor has formed. Scientifically, the study offers a concrete mechanism connecting an environmental exposome factor—iron-catalyzed oxidative stress—to a defined, transcriptionally characterized precancerous population, with ferroptosis resistance as the pivot. It also implies testable therapeutic hypotheses: if blocking mitochondrial remodeling or reversing ferroptosis resistance could prevent the persistence of the precancerous cells, early intervention might stop cancer before it starts. Toyokuni and his colleagues are careful to note that long-term studies will be needed to determine how giant-nucleus cells actually progress into tumor cells, whether such interventions can work, and whether nuclear shape combined with gene patterns can be validated as a diagnostic in larger patient cohorts. But the central message is already legible: some of the earliest chapters of cancer may be written in cells that have grown too large to be ignored.

The curving, parallel mountain ridges of the Sierra Madre Oriental are an eye-catching feature of northeastern Mexico’s landscape. The spot where these folds nestle up against Mexico’s second-largest metropolitan area captured the attention of an astronaut aboard the International Space Station, who took this photo on August 26, 2026.

Monterrey, the capital of the state of Nuevo León, is an industrial hub supporting heavy industries such as ironworks and steelworks, as well as manufacturing facilities for goods ranging from textiles to processed foods to glass and plastics. The metropolitan area is home to 5.3 million people, according to the 2020 census. And while the city has seen overall population growth since 1990, the number of people living within 5 kilometers (3 miles) of the city center has declined, researchers have found—a trajectory shared with many of Mexico’s metropolitan areas.

In Monterrey’s case, urban expansion runs up against some unforgiving terrain. Along the city’s southern edge, layers of limestone, deposited in the late Mesozoic era and then folded between about 80 and 50 million years ago, form the Sierra Madre Oriental. Over millions of years, weaker rock layers have eroded away, leaving behind the distinct ridgelines that bound Monterrey today.

The Río Santa Catarina carves through the mountains and onto the semiarid floodplain where the city lies. Because of the dry environment, the river carries little to no water for much of the time. But its channel is crucial for collecting runoff from summer rains and serves as an important natural area for plant and animal life within the city.

The river runs through Monterrey’s urban core and between several island-like protrusions of folded rock. One of these is the Sierra Las Mitras, a state nature reserve established in 2000. The mountain ridge rises approximately 1,500 meters (4,900 feet) over the city and provides a haven for wildlife. As conditions become cooler and wetter with higher elevations, vegetation turns from cacti and thorny shrubs on lower rocky slopes to oak and pine forests higher on the ridge. Cerro de la Silla (Mount Silla or Saddle Hill) is another prominent feature of the landscape, contrasting with the built environment.

Near the city’s border with the Sierra Madre Oriental sits Universidad de Monterrey, a host venue for the NASA Space Apps Challenge. This annual hackathon will take place in November 2026 in person and virtually at sites around the world. Participating teams use NASA and partner agency data to tackle challenges in fields such as software development, astrophysics, space exploration, and agriculture.

Astronaut photograph ISS075-E-70481 was acquired on August 26, 2026, with a Nikon Z9 digital camera using a focal length of 400 millimeters. It is provided by the ISS Crew Earth Observations Facility and the Earth Science and Remote Sensing Unit at NASA Johnson Space Center. The image was taken by a member of the Expedition 75 crew. The image has been cropped and enhanced to improve contrast, and lens artifacts have been removed. The International Space Station Program supports the laboratory as part of the ISS National Lab to help astronauts take pictures of Earth that will be of the greatest value to scientists and the public, and to make those images freely available on the internet. Additional images taken by astronauts and cosmonauts can be viewed at the NASA/JSC Gateway to Astronaut Photography of Earth. Story by Lindsey Doermann.

Downloads

August 26, 2026

JPEG (14.83 MB)

References & Resources

• International Parks, Sierra de las Mitras. Accessed September 10, 2026.
• NASA Earth Observatory (2020, November 27) A Sliver of Mexico’s “Mother Mountain Range.” Accessed September 10, 2026.
• NASA Earth Observatory (2017, May 10) Mount Silla and Monterrey. Accessed September 10, 2026.
• NASA Space Apps Challenge (2026) Monterrey. Accessed September 10, 2026.
• Universidad Autónoma de Nuevo León, La importancia ambiental del Río Santa Catarina. Accessed September 10, 2026.

You may also be interested in:

Stay up-to-date with the latest content from NASA as we explore the universe and discover more about our home planet.

Great Balls of Fire

4 min read

An astronaut on the International Space Station was surprised to photograph a shower of light streaking through the darkness while…

Article

The World Cup From 250 Miles Up

4 min read

Over the years, astronauts aboard the International Space Station have photographed several of the cities hosting the 2026 FIFA World…

Article

Shaping the Emerald City

4 min read

The hills and basins of Seattle, Washington, have been sculpted by glaciers and modified by humans.

Article

Keep Exploring

Discover More from NASA Earth Science

Subscribe to Earth Observatory Newsletters

Subscribe to the Earth Observatory and get the Earth in your inbox.

Earth Observatory Image of the Day

NASA's Earth Observatory brings you the Earth, every day, with in-depth stories and stunning imagery.

Explore Earth Science

Earth Science Data

Open access to NASA’s archive of Earth science data

The post Monterrey Amid Mountains appeared first on NASA Science.

Usando a sua experiência enquanto formadora de análise de dados, Beatriz Duarte defende os benefícios do Python e a combinação entre conhecimento técnico, pensamento analítico e aplicação prática.

The post Python na análise de dados: ferramenta indispensável ou competência sobrevalorizada? appeared first on Tek Notícias.

Thirty years after a small group of European professors of geriatric medicine first warned that the continent’s fastest-growing population was being cared for by physicians who had never been formally trained to care for them, the program they created to fix the problem is marking its anniversary with a scientific milestone of its own. A new special article published in European Geriatric Medicine documents the research output of the most recent graduating cohort of the European Academy for Medicine of Ageing, or EAMA, and in doing so offers a rare longitudinal measure of how a structured, pan-European leadership program in geriatric medicine translates into scholarly productivity, professional advancement and, ultimately, better care for older people.

The new paper, titled “‘Highlights of latest EAMA’: generation research outputs of the 30-year anniversary cohort,” was authored by Thomas Münzer of the Geriatric Clinic St. Gallen in Switzerland, Hannes B. Stähelin of Basel, and Barbara van Munster of the University of Groningen Medical School in the Netherlands, writing on behalf of the EAMA Board. It arrives at a moment when the demographic arithmetic of Europe has made the question of geriatric capacity more urgent than ever: the proportion of people over 65 continues to climb, multimorbidity, frailty and polypharmacy have become the daily reality of hospital medicine, and health systems across the continent still struggle to recruit and retain physicians trained specifically in the medicine of ageing. The article’s premise is simple but rarely examined with this degree of rigor — if you invest systematically in the education of mid-career geriatricians, what do you get back?

To understand the significance of the anniversary cohort’s research output, one has to go back to the early 1990s, when the group of European Professors in Medical Gerontology published a stark assessment in the journal Age and Ageing. Writing in 1994, Stähelin and colleagues documented that medical gerontology was taught unevenly, and in many countries not at all, in European medical schools. Geriatric medicine, despite being one of the few specialties whose patient population was guaranteed to expand every single year, was frequently a subordinate unit within internal medicine, staffed by physicians who had acquired their expertise on the job rather than through dedicated training. The professors’ conclusion was that Europe needed not merely more geriatricians but a new cadre of academic leaders — clinicians who could teach, publish, shape curricula and advocate for the specialty within their national health systems.

That diagnosis led, in 1995, to the founding of the European Academy for Medicine of Ageing, an intensive postgraduate program deliberately modeled on leadership academies rather than conventional continuing medical education. EAMA’s structure has remained remarkably stable across its three decades: a small, competitively selected cohort of physicians, typically already experienced clinicians, is brought together for a series of residential courses spread over roughly two years, interspersed with mentored projects that require participants to produce original scholarly work. The curriculum spans the full breadth of the medicine of ageing — from the biology of ageing and the physiology of frailty, through geriatric syndromes such as falls, delirium, incontinence and sarcopenia, to the organizational science of acute geriatric units, nursing home medicine, rehabilitation and end-of-life care. Crucially, faculty are drawn from across Europe, exposing participants to radically different national models of geriatric care and building a professional network that persists long after the formal courses end.

The “reloaded” reform of the program, described in a 2018 paper by Roller-Wirnsberger and colleagues in European Geriatric Medicine, formalized what three decades of experience had taught the academy’s faculty. That paper set out explicit competencies and standards for a European leadership program in geriatric medicine, defining what a graduate of EAMA should be able to do: not just diagnose and treat, but design services, lead multidisciplinary teams, mentor juniors, conduct and critique research, and represent the specialty at institutional and governmental levels. The competency framework aligned the academy with modern medical-education theory, in which learning objectives are specified in advance and assessed rather than assumed. It is against this framework that the anniversary cohort’s performance, as documented in the new article, can be read as an evaluation of the program itself.

The central finding of the new special article is that the latest cohort of EAMA graduates has generated a substantial body of research output — the “generation research outputs” of the title — spanning peer-reviewed publications, presentations and ongoing projects in geriatric medicine. Each participant in the program is expected to develop a scholarly project under faculty mentorship, moving from a research question through protocol design, data collection and analysis to presentation and, ideally, publication. For the 30-year anniversary cohort, the academy compiled and highlighted these outputs, creating what the authors describe as the “Highlights of latest EAMA” — a curated snapshot of what a single generation of emerging European geriatric leaders produced during and immediately after their training.

Why does this matter beyond the individual careers involved? The technical answer lies in how research capacity compounds. A single published paper changes one evidence base marginally; a cohort of trained researchers who continue publishing changes the trajectory of an entire specialty. Geriatric medicine has historically been under-represented in high-impact clinical research relative to the burden of disease it manages. Conditions such as delirium, frailty and multimorbidity were for decades excluded from major trials or treated as confounders rather than outcomes, precisely because the specialty lacked enough investigator-trained clinicians to insist on their inclusion. Programs like EAMA attack that bottleneck at its root: every graduate who learns to design a study, secure a mentor and navigate the publication pipeline becomes a node through which clinical questions from the bedside can flow into the literature and back.

The pedagogical machinery behind that outcome is worth examining, because it explains why the anniversary cohort’s productivity is treated by the authors as more than a curiosity. EAMA’s residential courses are built around case-based, small-group learning in which participants bring real clinical and organizational problems from their home institutions and work them through with international faculty. The mentored projects between courses impose deadlines and accountability — the two ingredients that, as anyone who has supervised doctoral students knows, most reliably convert good intentions into submitted manuscripts. The academy also functions as a peer-review incubator: draft papers are critiqued by senior European geriatricians before submission, giving participants exposure to the standards of international journals at a stage of their careers when feedback is most formative.

The anniversary article also carries a personal and institutional poignancy. Hannes B. Stähelin, one of the co-authors, is identified in the publication as deceased; he was among the founding professors whose 1994 analysis launched the academy, and his presence on the author line of a paper published in 2026 spans the full thirty-year arc of the program. The continuity from the GEPMG position paper through the 2002 retrospective review of the academy’s first years, published in Gerontology, through the 2018 competency framework, and now to this documentation of cohort research output, constitutes something rare in medical education: a thirty-year, multi-generation audit trail of a single intervention in specialty training, documented by the people who built it.

For health systems, the implications are concrete. Europe’s national models of geriatric care differ enormously — from the fully established departments of the United Kingdom and the Netherlands to countries where geriatrics is still fighting for recognition as an independent specialty. EAMA’s cohorts deliberately mix these national traditions, so that a geriatrician from a country without an acute geriatric unit model trains alongside colleagues who run such units daily. The research outputs of the anniversary cohort, the authors suggest, function as a form of technology transfer: projects conceived in one system are published in international journals and become adaptable blueprints for colleagues elsewhere. In an era when the European Union explicitly tracks health-workforce capacity, an academy that reliably produces clinicians who can lead services and generate evidence is a strategic asset, not a professional courtesy.

The article is also, implicitly, an argument about how educational interventions should be evaluated. Medical education research is notoriously dominated by satisfaction surveys and self-reported confidence measures, which correlate weakly with actual performance change. Research output — publications generated, projects completed, academic positions attained — is a harder, more objective endpoint, and the EAMA Board’s decision to compile and publish the anniversary cohort’s outputs signals a commitment to accountability by measurable results. It is a methodology other postgraduate leadership programs in medicine, from palliative care to rural health, could plausibly adopt: define the competencies, train against them, and then report what the trainees actually produced.

The publication timeline of the article itself — received in December 2025, revised in April 2026, accepted in June and published on 6 July 2026 in European Geriatric Medicine, the journal of the European Geriatric Medicine Society — places it squarely in the anniversary year it commemorates. As Europe’s population ages at a pace with no historical precedent, the question the founding professors asked in 1994 — who will teach the teachers, and who will lead the specialty? — has an answer that can now be pointed to in print: thirty years of EAMA cohorts, and a newest generation whose scholarly work is documented, highlighted and, the academy clearly hopes, replicated by the cohorts to come.

Idiopathic pulmonary fibrosis, a relentlessly progressive and fatal scarring disease of the lungs, has long frustrated clinicians with only two approved drugs that slow but cannot reverse its course. Now, a team of researchers in Taiwan has identified a surprising new player in the disease’s destructive machinery: doublecortin-like kinase 1, or DCLK1, a kinase better known for its role in cancer stem cells. Their study, published in the Journal of Biomedical Science, demonstrates that DCLK1 drives fibroblast activation in the lung and that blocking it—either genetically or with an oral inhibitor—slows fibrosis and preserves lung function in mice. The findings position DCLK1 as a promising therapeutic target in one of medicine’s most stubborn diseases.

The research, led by Lee-Yuan Lin, Wun-Hao Cheng, Chien-Huang Lin and Bing-Chang Chen of Taipei Medical University, together with collaborators at National Taiwan University Hospital and Universitas Gadjah Mada, began with a question that has lingered in the literature. Gene expression analyses had previously hinted that DCLK1 might be implicated in IPF, and earlier work reported that the kinase is markedly enhanced in the alveolar epithelial cells of patients with pulmonary fibrosis and in mice with bleomycin-induced fibrosis. But its function in fibroblast activation—the cellular engine of fibrosis—had remained unexplained.

To begin untangling that role, the team mined a publicly available single-cell RNA sequencing data set containing more than 312,000 cells from healthy lungs, IPF lungs, and lungs with chronic obstructive pulmonary disease. After stringent quality control filtering, they focused on roughly 240,000 cells from the control and IPF groups and mapped DCLK1 expression across the major lung cell lineages: epithelial, endothelial, lymphoid, myeloid, and stromal cells. The signal was unmistakable. DCLK1 was expressed across many cell populations, but the highest expression appeared in the stromal compartment, particularly in myofibroblasts—the specialized, contractile fibroblasts that churn out the extracellular matrix and stiffen lung tissue in IPF.

Human tissue told the same story. The researchers examined lung samples from eleven patients with IPF, obtained during lung transplantation or surgery, alongside fourteen nonfibrotic control samples. Histological staining with hematoxylin and eosin and Masson trichrome confirmed the expected picture of interstitial consolidation and collagen deposition in the IPF specimens. More importantly, immunohistochemistry revealed that both total DCLK1 and its phosphorylated, activated form were significantly upregulated in the fibrotic lung interstitium compared with control tissue. DCLK1, in other words, was not merely present in scarred lungs—it was switched on.

DCLK1 is an intriguing molecule to find at the center of a fibrotic process. It is a serine/threonine kinase belonging to the calcium/calmodulin-dependent kinase family, distinguished by two microtubule-binding domains. In oncology, DCLK1 overexpression has been documented in colorectal, pancreatic, gastric, renal, and hepatocellular carcinomas, where it correlates with poor prognosis, high recurrence, and metastasis, promoting tumor initiation and the epithelial–mesenchymal transition in cancer stem cells. It has also been linked to inflammatory signaling in SARS-CoV-2 infection, where inhibiting it blocks proinflammatory caspase-1/interleukin-1β signaling. The new study extends this portfolio of mischief to the fibrotic lung.

To test causality rather than mere correlation, the researchers turned to mice. They crossed animals carrying loxP sites flanking exon 3 of the DCLK1 locus with Pgk1-RFP-Cre/ERT2 transgenic mice, generating a system in which tamoxifen administration triggers global deletion of the Dclk1 gene. When these DCLK1 knockout mice and littermate controls were given intratracheal bleomycin, a chemotherapy drug used to induce pulmonary fibrosis in laboratory animals, the difference was striking. Knockout mice showed far less lung infiltration and collagen deposition, reduced numbers of cells staining positive for DCLK1 together with fibroblast surface protein and alpha-smooth muscle actin, and significantly lower levels of the profibrotic proteins fibronectin, α-SMA, and connective tissue growth factor, or CTGF.

The protective effect extended well beyond molecular markers. Using the FlexiVent FX system to measure lung mechanics, the team found that bleomycin treatment significantly reduced respiratory system compliance and pressure–volume performance and increased the normalized work of breathing in control mice—hallmarks of a stiffening, fibrotic lung. In the DCLK1 knockout animals, these functional deficits were substantially attenuated. In vivo microcomputed tomography, acquired at 34.75-micrometer voxel resolution, painted the morphological counterpart: bleomycin caused parenchymal destruction and volume loss in control lungs, while knockout mice retained lung structure and volume. Density histograms shifted toward fibrotic tissue in wild-type animals but stayed largely preserved in the knockouts, and peripheral blood neutrophil percentages, which climbed after bleomycin injury, were significantly reduced in the knockout group.

With the in vivo evidence established, the investigators dissected the molecular wiring in cultured normal human lung fibroblasts. Transforming growth factor beta, the master profibrotic cytokine, induced DCLK1 phosphorylation within 30 minutes and DCLK1 expression within 8 hours. Chromatin immunoprecipitation assays showed that after TGF-β stimulation, both Smad3—the canonical transcriptional mediator of TGF-β signaling—and the nuclear factor kappa B subunit p65 enriched at the DCLK1 promoter, indicating that TGF-β switches on DCLK1 through both Smad-dependent and noncanonical NF-κB pathways. Silencing DCLK1 with small interfering RNA then blunted the fibroblast’s profibrotic response, reducing TGF-β-induced expression of fibronectin, collagen 1A1, α-SMA, and CTGF.

The pathway, however, does not stop there. The team found that TGF-β also phosphorylated Akt, and that transfecting fibroblasts with a dominant-negative Akt construct reduced TGF-β-induced DCLK1 phosphorylation and the expression of fibronectin and CTGF—placing Akt upstream of DCLK1. Downstream, DCLK1 knockdown reduced Smad3 phosphorylation while DCLK1 overexpression enhanced it. Coimmunoprecipitation revealed a physical association between DCLK1 and Smad3, and immunofluorescence microscopy showed the two proteins colocalizing in the nucleus within 30 minutes of TGF-β treatment. A ChIP assay using a DCLK1 antibody pulled down DNA from the Smad3-binding region of the CTGF promoter, and pretreatment with the selective DCLK1 inhibitor DCLK1-IN-1 reduced TGF-β-induced CTGF expression. Together, the results sketch an Akt/DCLK1/Smad3 axis through which TGF-β drives the production of connective tissue growth factor, a potent profibrotic mediator.

The clinical payoff came in the pharmacological arm of the study. Mice receiving oral DCLK1-IN-1 at 10 milligrams per kilogram daily, beginning on day 7 after bleomycin instillation and continuing until day 28, showed visibly reduced fibrotic progression on histology, lower expression of fibronectin, α-SMA, and CTGF in lung tissue and lysates, preserved pulmonary compliance, improved pressure–volume loops, and reduced work of breathing. Serial microCT scans on days 7, 17, and 27 documented less severe fibrotic remodeling in the treated animals, with lung attenuation histograms showing a smaller fraction of dense, nonaerated voxels. Blood neutrophil counts were also lower. In short, a pill-like oral inhibitor measurably slowed the disease in a model that mirrors the human condition.

The implications are significant because the current therapeutic landscape for IPF is so thin. Only nintedanib, a tyrosine kinase inhibitor targeting growth factor receptors, and pirfenidone, which suppresses TGF-β production and activity, are approved by the US Food and Drug Administration, and both merely slow progression. The recent failure of pamrevlumab, a monoclonal antibody against CTGF, in the phase 3 ZEPHYRUS-1 trial suggested that targeting downstream fibrotic end products alone may be insufficient—pointing to the value of upstream signaling regulators such as DCLK1. Adding to the appeal, a DCLK1 inhibitor has already been shown to prevent inflammatory responses in acute lung injury, hinting at dual anti-fibrotic and anti-inflammatory potential.

The authors are careful to note limitations. DCLK1 is expressed across multiple lung cell types, and the tamoxifen-inducible knockout used here was global rather than cell-type-specific, so the contributions of fibroblasts versus epithelial, endothelial, and immune cells could not be fully separated. Human control tissue, as in most fibrosis studies, came from heterogeneous sources, including tumor-adjacent lung. The precise subcellular mechanics of the DCLK1–Smad3 interaction, whether DCLK1 inhibition can promote fibrosis resolution rather than merely slow progression, and the systemic safety of long-term DCLK1 blockade—all relevant given the kinase’s role in cancer and other processes—remain open questions.

Even so, the convergence of evidence is striking: DCLK1 is upregulated in human IPF, amplified in experimental fibrosis, mechanistically coupled to the TGF-β–Smad3 engine of fibroblast activation, and its suppression by both genetics and a small molecule preserves lung structure and function. What began as a cancer stem cell marker has now emerged, unexpectedly, as a central node in the scarring of the lung—offering fresh hope that a disease long considered irreversible may one day be stopped at its molecular source.